Endocrine Society member Matthias Tschöp, MD, has been awarded the 2026 Rolf Luft Award for outstanding groundbreaking scientific contributions to fields of diabetes and obesity basic research leading to important clinical implications. He shares the award with Richard Dennis DiMarchi from Indiana University in Bloomington.
Tschöp, president of Ludwig-Maximilians-Universität München (LMU), is an internationally renowned physician and medical researcher who previously led Helmholtz Munich and was vice president of the Helmholtz Association for Health Research. The duo were recognized for advances in peptide chemistry and the development of novel duel and triple agonists for the treatment of diabetes and obesity.
Several versions of these so-called gut hormone poly-agonists have advanced through clinical trials. One class representative, with the same active peptide ingredient named tirzepatide advanced by Eli Lilly, has already been FDA approved for treating type 2 diabetes in 2022 as Mounjaro and obesity in 2023 as Zepbound.
Treatment of obese patients with tirzepatide decreased patients’ body weight more than 20%, an excess weight where obesity is typically defined.
Endocrine News published a clinical update in Research Highlights on 26 May 2026.
The item focuses on Matthias Tschöp, MD, Receives 2026 Rolf Luft Award.
Review the original article for the full source wording and details.